Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: “We would like to thank the dedicated physicians and pyoderma gangrenosum patients for their participation in this ...

Citeline and Norstella have completed a merger, first announced in June, to create one of the largest players in the pharmaceutical intelligence category. Citeline provides intelligence, data, and ...

A former scientist at Google's DeepMind who co-developed the AlphaFold2 protein prediction platform, Dr Simon Kohl, has launched his own venture applying artificial intelligence to drug discovery ...

There’s no specific diet for people with microscopic colitis, but eating foods like plain rice, low fat dairy, and bananas may help symptoms. It’s also best to avoid alcohol and caffeine. Shar ...

Brown recluse bites often start with a blister at the center of a small, painful wound. The tissue around it can appear red and bruised. Symptoms can quickly progress to more serious swelling and ...

InflaRx’s vilobelimab met the bar for futility in a Phase III trial for the rare skin disease pyoderma gangrenosum. May 28, 2025 · 2 min read · Tristan Manalac Clinical research ...

MUNICH, Germany and WILMINGTON, DE, USA I May 28, 2025 I DEBRA Research gGmbH, a global non-profit organization dedicated to advancing research and drug development for those affected by Epidermolysis ...

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. He can be reached at [email protected], ...